Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | HTT | P42858 | 6/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8809521 | 0.81 | MAPT (0.40) | MAPTHTTLMNAALDH1A1KMT2A | |
| SCHEMBL8811728 | 0.81 | ALDH1A1 (0.44) | MAPTHTTLMNAALDH1A1KMT2A | |
| SCHEMBL4829285 | 0.81 | MAPT (0.38) | MAPTHTTLMNAALDH1A1KMT2A | |
| SCHEMBL8814038 | 0.79 | LMNA (0.43) | MAPTHTTLMNAALDH1A1KMT2A | |
| SCHEMBL8808441 | 0.79 | ALDH1A1 (0.38) | MAPTHTTLMNAALDH1A1KMT2A | |
| SCHEMBL4988091 | 0.76 | MAPT (0.39) | MAPTHTTLMNAALDH1A1KMT2A | |
| SCHEMBL4989105 | 0.76 | SMN1; SMN2 (0.50) | MAPTHTTLMNAALDH1A1NPC1 | |
| SCHEMBL4983375 | 0.75 | ALDH1A1 (0.38) | MAPTHTTLMNAALDH1A1KMT2A | |
| SCHEMBL4829348 | 0.72 | S1PR4 (0.39) | MAPTHTTLMNAALDH1A1KMT2A | |
| SCHEMBL14093773 | 0.71 | MEN1 (0.46) | MAPTHTTLMNAALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576203-B2 | Method for producing cyclic diamine derivative | KOWA CO., LTD. (JP) | 2009-08-18 | — | — | US | disclosed |
| US-7576203-B2 | Method for producing cyclic diamine derivative | KOWA CO., LTD. (JP) | 2009-08-18 | — | — | US | disclosed |
| US-7560547-B2 | Hydroxyalkyl cyclic diamine compounds | KOWA CO., LTD. (JP) | 2009-07-14 | — | — | US | disclosed |
| US-7560547-B2 | Hydroxyalkyl cyclic diamine compounds | KOWA CO., LTD. (JP) | 2009-07-14 | — | — | US | disclosed |
| US-20080045714-A1 | Method for Producing Cyclic Diamine Derivative | KOWA CO., LTD (JP) | 2008-02-21 | — | — | US | disclosed |
| US-20080045714-A1 | Method for Producing Cyclic Diamine Derivative | KOWA CO., LTD (JP) | 2008-02-21 | — | — | US | disclosed |
| US-20070088159-A1 | HYDROXYALKYL CYCLIC DIAMINE COMPOUNDS | KOWA CO., LTD. (JP) | 2007-04-19 | — | — | US | disclosed |
| US-20070088159-A1 | HYDROXYALKYL CYCLIC DIAMINE COMPOUNDS | KOWA CO., LTD. (JP) | 2007-04-19 | — | — | US | disclosed |
| EP-1767527-A1 | METHOD FOR PRODUCING CYCLIC DIAMINE DERIVATIVE | Kowa Co., Ltd. (JP) | 2007-03-28 | — | — | EP | disclosed |
| EP-1767527-A1 | METHOD FOR PRODUCING CYCLIC DIAMINE DERIVATIVE | Kowa Co., Ltd. (JP) | 2007-03-28 | — | — | EP | disclosed |
| EP-0609960-B1 | New N-heteroarylamide derivatives as inhibitors of acyl coenzyme A: cholestrol acyl transferase | PFIZER (US) | 1999-03-03 | — | — | EP | disclosed |
| US-5656634-A | N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT) | PFIZER INC. (US) | 1997-08-12 | — | — | US | disclosed |
| US-5596001-A | 4-aryl-3-(heteroarylureido)quinoline derivatves | PFIZER INC. (US) | 1997-01-21 | — | — | US | disclosed |
| US-5583147-A | INHIBITORS OF ACYL-COENZYME A: CHOLESTEROL O-TRANSFERASE; ANTIHYPERCHOLESTEROLEMIC AND/OR ANTIATHEROSCLEROTIC AGENTS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-12-10 | — | — | US | disclosed |
| US-5491152-A | Derivatives of cyclic ethers and sulfides for the treatment of atherosclerosis | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-02-13 | — | — | US | disclosed |
| US-5362878-A | Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT) | PFIZER INC. (US) | 1994-11-08 | — | — | US | disclosed |
| EP-0609960-A1 | New N-heteroarylamide derivatives as inhibitors of acyl coenzyme A: cholestrol acyl transferase | PFIZER INC. (US) | 1994-08-10 | — | — | EP | disclosed |
| EP-0590094-A1 | 4-ARYL-3-(HETEROARYLUREIDO)QUINOLINE DERIVATIVES | PFIZER INC. (US) | 1994-04-06 | — | — | EP | disclosed |
| WO-1992019614-A1 | 4-ARYL-3-(HETEROARYLUREIDO)QUINOLINE DERIVATIVES | PFIZER INC. (US) | 1992-11-12 | — | — | WO | disclosed |
| EP-0418071-A2 | New N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase | PFIZER INC. (US) | 1991-03-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045714-A1 | Method for Producing Cyclic Diamine Derivative | SAT1, ACAT2, NAT1 | MAPT 767/4885HTT 1507/4885LMNA 3999/4885 |
| US-20070088159-A1 | HYDROXYALKYL CYCLIC DIAMINE COMPOUNDS | HDHD5, DDC, DDT | MAPT 4009/4885HTT 373/4885LMNA 4773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.